Hortobagyi, G.N.
85  results:
Search for persons X
?
1

Tucatinib versus placebo added to trastuzumab and capecitab..:

Curigliano G ; Mueller V ; Borges V...
info:eu-repo/semantics/altIdentifier/pmid/34954044.  , 2022
 
?
2

21-Gene Assay to Inform Chemotherapy Benefit in Node-Positi..:

Kalinsky, K ; Barlow, W.E ; Gralow, J.R...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096864/.  , 2021
 
?
3

Long-term survival outcomes of triple-receptor negative bre..:

Reddy, S M ; Barcenas, C H ; Sinha, A K...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765226/.  , 2018
 
?
 
?
7

Circulating tumor cells (CTC) are associated with defects i..:

Mego, M ; Gao, H ; Cohen, E. N...
info:eu-repo/semantics/altIdentifier/wos/WOS:000419056800001.  , 2016
 
?
8

Meta-analysis of stomatitis in clinical studies of everolim..:

Rugo, H. S ; Hortobagyi, G. N ; Yao, J...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4769991/.  , 2016
 
?
9

Clinical benefit from neoadjuvant chemotherapy in oestrogen..:

Delpech, Y ; Coutant, C ; Hsu, L...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3566807.  , 2013
 
?
 
?
 
?
13

A network-based, integrative study to identify core biologi..:

Dutta, B ; Pusztai, L ; Qi, Y...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3304402.  , 2012
 
?
 
?
 
1-15